INMUNE BIO INC. Increase (Decrease) in Other Receivables
INMUNE BIO INC. (INMB) reported Increase (Decrease) in Other Receivables of $97.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOtherReceivables · last filed 2026-08-06
- INMUNE BIO INC. increase (decrease) in other receivables for the quarter ending 2026-06-30 was $63.00K, a 84.89% decline year-over-year.
- INMUNE BIO INC. increase (decrease) in other receivables for the quarter ending 2026-03-31 was $34.00K.
- INMUNE BIO INC. increase (decrease) in other receivables for the quarter ending 2025-12-31 was -$503.00K.
- INMUNE BIO INC. increase (decrease) in other receivables for the quarter ending 2025-09-30 was $210.00K, a 412.20% increase year-over-year.
- INMUNE BIO INC. increase (decrease) in other receivables for fiscal 2025 was $29.00K.
- INMUNE BIO INC. increase (decrease) in other receivables for fiscal 2024 was -$309.00K, a 276.57% decline from fiscal 2023.
- INMUNE BIO INC. increase (decrease) in other receivables for fiscal 2023 was $175.00K.
- INMUNE BIO INC. increase (decrease) in other receivables for fiscal 2022 was -$229.00K, a 147.91% decline from fiscal 2021.
| Period end | Increase (Decrease) in Other Receivables 3 month | Increase (Decrease) in Other Receivables 6 month | Increase (Decrease) in Other Receivables 9 month | Increase (Decrease) in Other Receivables 12 month |
|---|---|---|---|---|
| 2026-06-30 | $63.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $97.00K 10-Q · filed 2026-08-06 | -$406.00K derived: sum of 3 quarters · filed 2026-08-06 | -$196.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $34.00K 10-Q · filed 2026-05-07 | -$469.00K derived: sum of 2 quarters · filed 2026-05-07 | -$259.00K derived: sum of 3 quarters · filed 2026-05-07 | $158.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | -$503.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | -$293.00K derived: sum of 2 quarters · filed 2026-03-30 | $124.00K derived: sum of 3 quarters · filed 2026-08-06 | $29.00K 10-K · filed 2026-03-30 |
| 2025-09-30 | $210.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-30 | $627.00K derived: sum of 2 quarters · filed 2026-08-06 | $532.00K 10-Q · filed 2025-10-30 | $449.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $417.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $322.00K 10-Q · filed 2026-08-06 | $239.00K derived: sum of 3 quarters · filed 2026-08-06 | $280.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | -$95.00K 10-Q · filed 2026-05-07 | -$178.00K derived: sum of 2 quarters · filed 2026-05-07 | -$137.00K derived: sum of 3 quarters · filed 2026-05-07 | -$424.00K derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | -$83.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | -$42.00K derived: sum of 2 quarters · filed 2026-03-30 | -$329.00K derived: sum of 3 quarters · filed 2026-03-30 | -$309.00K 10-K · filed 2026-03-30 |
| 2024-09-30 | $41.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-30 | -$246.00K derived: sum of 2 quarters · filed 2025-10-30 | -$226.00K 10-Q · filed 2025-10-30 | $135.00K derived: sum of 4 quarters · filed 2025-10-30 |
| 2024-06-30 | -$287.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | -$267.00K 10-Q · filed 2025-08-07 | $94.00K derived: sum of 3 quarters · filed 2025-08-07 | $158.00K derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $20.00K 10-Q · filed 2025-05-08 | $381.00K derived: sum of 2 quarters · filed 2025-05-08 | $445.00K derived: sum of 3 quarters · filed 2025-05-08 | $161.00K derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | $361.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | $425.00K derived: sum of 2 quarters · filed 2025-03-27 | $141.00K derived: sum of 3 quarters · filed 2025-03-27 | $175.00K 10-K · filed 2025-03-27 |
| 2023-09-30 | $64.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-31 | -$220.00K derived: sum of 2 quarters · filed 2024-10-31 | -$186.00K 10-Q · filed 2024-10-31 | $62.00K derived: sum of 4 quarters · filed 2024-10-31 |
| 2023-06-30 | -$284.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | -$250.00K 10-Q · filed 2024-08-01 | -$2.00K derived: sum of 3 quarters · filed 2024-08-01 | -$22.00K derived: sum of 4 quarters · filed 2024-08-01 |
| 2023-03-31 | $34.00K 10-Q · filed 2023-05-03 | $282.00K derived: sum of 2 quarters · filed 2023-05-03 | $262.00K derived: sum of 3 quarters · filed 2023-11-01 | -$103.00K derived: sum of 4 quarters · filed 2023-11-01 |
| 2022-12-31 | $248.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-02 | $228.00K derived: sum of 2 quarters · filed 2023-11-01 | -$137.00K derived: sum of 3 quarters · filed 2023-11-01 | -$229.00K 10-K · filed 2023-03-02 |
| 2022-09-30 | -$20.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-01 | -$385.00K derived: sum of 2 quarters · filed 2023-11-01 | -$477.00K 10-Q · filed 2023-11-01 | -$74.00K derived: sum of 4 quarters · filed 2023-11-01 |
| 2022-06-30 | -$365.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-07 | -$457.00K 10-Q · filed 2023-08-07 | -$54.00K derived: sum of 3 quarters · filed 2023-08-07 | |
| 2022-03-31 | -$92.00K 10-Q · filed 2023-05-03 | $311.00K derived: sum of 2 quarters · filed 2023-05-03 | ||
| 2021-12-31 | $403.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-02 | $478.00K 10-K · filed 2023-03-02 | ||
| 2021-09-30 | $75.00K 10-Q · filed 2022-11-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B |